Risks

Liquidity remains tight with a 0.47 current ratio and 0.32 quick ratio, leaving ZYXI more exposed than larger medtech peers to working-capital shocks and refinancing pressure.

Inventory days of 211 and payables days of 221 indicate a stretched cash cycle, which can constrain order fulfillment and supplier terms versus peers with faster turnover.

Negative interest coverage and sub-1.0 net debt to EBITDA suggest limited earnings cushion, increasing sensitivity to demand softness relative to better-capitalized competitors.

The balance-sheet profile leaves less flexibility to absorb reimbursement or demand volatility, so peer firms with stronger liquidity can defend growth and margins more effectively.

Opportunities

A negative net debt to EBITDA position provides some leverage headroom, which could support relative resilience if peers face tighter financing conditions.

High inventory and payables days can preserve near-term operating continuity, giving ZYXI more time to convert working capital than peers with thinner supplier buffers.

If demand stabilizes, the company’s existing distribution and reimbursement footprint could support incremental recovery, though peers with stronger liquidity may capture growth faster.

Working-capital normalization could improve cash generation from current levels, but the upside is limited by weaker liquidity than most direct medtech peers.

Overall Score

ZYXI’s forward positioning is constrained by weak liquidity and limited earnings coverage versus peers, while modest leverage headroom and working-capital flexibility provide only partial offset.